Nuvectis Total Current Liabilities from 2010 to 2024
| NVCT Stock | USD 4.95 0.15 2.94% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 7 M | Current Value 4.3 M | Quarterly Volatility 2.5 M |
Check Nuvectis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nuvectis Pharma's main balance sheet or income statement drivers, such as Interest Expense of 179.9 K, Selling General Administrative of 4.6 M or Selling And Marketing Expenses of 13.2 K, as well as many indicators such as Price To Sales Ratio of 510, Dividend Yield of 0.0 or PTB Ratio of 11.17. Nuvectis financial statements analysis is a perfect complement when working with Nuvectis Pharma Valuation or Volatility modules.
Nuvectis | Total Current Liabilities |
Latest Nuvectis Pharma's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Nuvectis Pharma over the last few years. Total Current Liabilities is an item on Nuvectis Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Nuvectis Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Nuvectis Pharma's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nuvectis Pharma's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Nuvectis Total Current Liabilities Regression Statistics
| Arithmetic Mean | 1,332,582 | |
| Geometric Mean | 51,299 | |
| Coefficient Of Variation | 184.54 | |
| Mean Deviation | 1,939,786 | |
| Median | 10,000 | |
| Standard Deviation | 2,459,103 | |
| Sample Variance | 6T | |
| Range | 7M | |
| R-Value | 0.73 | |
| Mean Square Error | 3T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 401,136 | |
| Total Sum of Squares | 84.7T |
Nuvectis Total Current Liabilities History
About Nuvectis Pharma Financial Statements
Nuvectis Pharma shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Nuvectis Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Nuvectis Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Nuvectis Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 7 M | 4.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.